Kewaunee Scientific (KEQU) Q1 2027 earnings review
Earnings Plunge as Project Timelines Stretch
Kewaunee Scientific's FY27 opened with a reversing trend, as the strong growth seen in FY26 evaporated. Revenue fell 6.7% YoY to $66.3M, and Net Income plunged 44.8% to $1.7M ($0.58 EPS). The core Lab Products Group (LPG) suffered from lower manufacturing volumes due to a challenging life sciences market. The only bright spot for profitability was the International segment, which managed to expand net earnings by 24% despite lower sales. While management insists quoting activity remains robust, the combination of extended project timelines, higher corporate expenses, and an elevated tax rate heavily compressed the bottom line.
🐂 Bull Case
Despite a 7.8% drop in International sales, the segment achieved a 23.5% increase in net earnings and a 13.9% boost in EBITDA, proving strong execution and a favorable margin mix on recent projects.
Sequential backlog ticked up to $169.0M from $165.9M in the prior quarter, providing a solid demand baseline once macroeconomic headwinds subside and clients release projects for manufacturing.
🐻 Bear Case
The Lab Products Group (LPG) saw sales fall 6.4% and segment EBITDA drop 13.1%. Weakness in the life sciences sector is actively eroding domestic manufacturing volumes.
Fixed corporate costs and one-time compensation adjustments severely impacted the bottom line, driving EPS down to $0.58 from $1.04 a year ago.
⚖️ Verdict: 🔴
Bearish. The post-acquisition (Nu Aire) growth tailwinds of FY26 are gone, leaving Kewaunee exposed to anemic life science market conditions. Until the backlog actually converts to revenue, earnings will remain depressed.
Key Themes
Disconnect Between Quoting and Execution
Management noted that 'quoting activity remains strong,' yet this positive narrative directly contradicts the hard data: LPG manufacturing volumes declined and consolidated revenue dropped 6.7%. The backlog, while up sequentially, is down substantially YoY ($169.0M vs $205.0M in 26Q1). Customers are asking for quotes but delaying actual purchase orders and site deliveries.
Macro: Extended Project Delivery Timelines
A continuing drag on revenue realization is the broader macroeconomic and geopolitical uncertainty. Customers in both domestic and international markets are pausing construction and laboratory build-outs. This stretches out the order-to-cash cycle and leaves Kewaunee's manufacturing capacity underutilized, directly pressuring margins.
International Margin Mix Optimization
The International segment was the primary driver of profitability stabilization. Sales fell 7.8% YoY to $15.5M, but a reversing trend in profitability emerged as segment net earnings jumped 23.5% to $794,000. Management capitalized on a highly favorable mix of higher-margin projects, proving their selective bidding strategy is shielding the bottom line overseas.
Nu Aire Integration and Biological Safety Expansion
Kewaunee continues to leverage its Nu Aire acquisition, fully integrating its biological safety cabinets, CO2 incubators, and specialized laboratory equipment into the core Lab Products Group (LPG). While volume is currently soft, the expanded product portfolio into critical containment lab furniture positions the company well for when life sciences capital expenditure eventually unfreezes.
Corporate Expenses and Tax Rate Drag
Pre-tax earnings were dragged down by a structural increase in the effective tax rate (28.0% vs 19.4% in the prior year), driven by a higher mix of international earnings. Concurrently, the Corporate segment EBITDA loss widened from $2.3M to $3.3M due to a strategic decision to settle specific long-term incentive awards in cash rather than shares to avoid shareholder dilution.
Deleveraging and Balance Sheet Discipline
Despite the earnings crunch, Kewaunee maintained stable footing by aggressively managing its balance sheet. Long-term debt (excluding the sale-leaseback liability) declined sequentially from $15.1M to $13.8M. The company's debt-to-equity ratio net of the sale-leaseback now sits at a very healthy 0.25-to-1, ensuring they have the liquidity to weather the ongoing construction delay cycle.
Other KPIs
Stable sequentially (up from $165.9M at the end of FY26) but decelerating heavily YoY (down from $205.0M in 26Q1). While the sequential stabilization is encouraging, the YoY contraction underscores the prolonged slowdown in new large-scale project awards.
Decelerating from 13.9% in the prior year quarter. Despite solid cost management and a stronger education market offset, the raw lack of manufacturing volumes from the life sciences sector eroded fixed-cost leverage.
Guidance
Management continues its policy of withholding specific forward-looking revenue and earnings guidance, citing the severe volatility in project delivery timelines tied to the laboratory construction market.
Key Questions
Conversion of Quoting Activity
You mentioned quoting activity remains 'strong across our markets.' What specific macroeconomic or interest-rate triggers are clients waiting for before they release these quoted projects into the manufacturing phase?
Life Sciences Weakness
With the noted 'challenging life sciences market conditions' impacting LPG manufacturing volumes, are you seeing any divergence in demand between pharmaceutical, biotech, and academic sub-verticals?
Tax Rate Sustainability
The effective tax rate spiked due to the higher mix of international earnings. If LPG volumes remain depressed in the near term, should we expect this elevated ~28% tax rate to be the new normal for FY27?